Results from a phase I clinical trial demonstrated that the CSF-1R-targeted monoclonal antibody RG7155 depleted CSF-1R+ CD163+ macrophages in tumor tissues and had significant clinical benefit in patients with diffuse-type giant cell tumors. The gene discussed is CSF1R; the disease is neoplasm.